Table 4.
Relationship between aspirin-associated gastroduodenal injuries and antiulcer drug treatment
| Total n = 1454 |
AMB n = 935 (64.3) |
Erosion n = 425 (29.2) |
p valuea | Ulcer n = 94 (6.5) |
p valueb | |
|---|---|---|---|---|---|---|
| No antiulcer drug (%) | 690 (47.5) | 390 (41.7) | 242 (56.9) | <0.0001 | 58 (61.7) | 0.0003 |
| PPI alone (%) | 243 (16.7) | 193 (20.6) | 43 (10.1) | <0.0001 | 7 (7.4) | 0.0014 |
| H2RA alone (%) | 263 (18.1) | 192 (20.5) | 58 (13.6) | 0.0025 | 13 (13.8) | 0.1367 |
| CAD alone (%) | 171 (11.8) | 98 (10.5) | 62 (14.6) | 0.0364 | 11 (11.7) | 0.7246 |
| PGA alone (%) | 2 (0.1) | 1 (0.1) | 1 (0.2) | 0.5275 | 0 (0.0) | 1.0000 |
| PPI + H2RA (%) | 2 (0.1) | 1 (0.1) | 1 (0.2) | 0.5275 | 0 (0.0) | 1.0000 |
| PPI + CAD (%) | 33 (2.3) | 26 (2.8) | 7 (1.6) | 0.2558 | 0 (0.0) | 0.1606 |
| PPI + PGA (%) | 1 (0.1) | 0 (0.0) | 0 (0.0) | 1.0000 | 1 (1.1) | 0.0914 |
| CAD + PGA (%) | 1 (0.1) | 0 (0.0) | 1 (0.2) | 0.3125 | 0 (0.0) | 1.0000 |
| H2RA + CAD (%) | 47 (3.2) | 34 (3.6) | 9 (2.1) | 0.1803 | 4 (4.3) | 0.7716 |
| PPI + H2RA + CAD (%) | 1 (0.1) | 0 (0.0) | 1 (0.2) | 0.3125 | 0 (0.0) | 1.0000 |
Association of gastroduodenal injuries with concomitant use of antiulcer drug was analyzed using data of 1454 participants. The proportions of participants who received each category of antiulcer treatment were examined in the three groups of gastroduodenal conditions. Those in each treatment category were evaluated between the erosion group or the ulcer group versus the AMB group with Fisher’s exact test
PPI proton pump inhibitor, H2RA histamine 2-receptor antagonist, CAD cytoprotective antiulcer drug, PGA prostaglandin analog
a p value between AMB and Erosion
b p value between AMB and Ulcer